# A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Source: https://onco.cc/trials/nct05879055/  
OnCo record `nct05879055` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PM8002 in neuroendocrine tumours, run by Biotheus Inc., active and no longer recruiting.

## Summary

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN is a phase 2 interventional study registered as NCT05879055 by Biotheus Inc., with 31 participants enrolled, started 2023-05-17 and due to reach its primary completion in 2027-01-01. Interventions recorded: PM8002 and FOLFIRI.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05879055
- Phase: 2
- Setting: A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm
- Sponsor: Biotheus Inc.
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT05879055: https://clinicaltrials.gov/study/NCT05879055

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- drugs: [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct05879055.json